|Nome||Titolo||Retribuzione||Esercitate||Anno di nascita|
|Mr. Brendan Kennedy||Chairman, Pres & CEO||592,15k||6,35M||1972|
|Mr. Michael C. Kruteck||Chief Financial Officer||N/D||N/D||1963|
|Mr. Jon Edward Levin||Chief Operating Officer||N/D||N/D||1970|
|Mr. Joshua Eades||Chief Scientific Officer||N/D||N/D||N/D|
|Ms. Dara Redler||Gen. Counsel & Corp. Sec.||N/D||N/D||N/D|
|Ms. Rita Seguin||Chief HR Officer||N/D||N/D||N/D|
|Mr. Sascha Mielcarek||Managing Director of Europe||N/D||N/D||N/D|
|Mr. John Andonoff||Sr. VP of Global Medical Sales Devel.||N/D||N/D||N/D|
|Ms. Kristina Adamski||Exec. VP of Corp. Affairs||N/D||N/D||N/D|
Tilray, Inc. engages in the research, cultivation, processing, and distribution of medical cannabis. The company offers its products to patients, physicians, clinics, pharmacies, governments, and hospitals; and for researchers for commercial purposes, as well as compassionate access and clinical research applications. It operates in Argentina, Australia, Canada, Chile, Croatia, Cyprus, Germany, Israel, New Zealand, Portugal, Spain, Africa, Switzerland, the United States, Malta, and the United Kingdom. The company was incorporated in 2018 and is headquartered in Nanaimo, Canada.
L'ISS Governance QualityScore di Tilray, Inc. al N/D è N/D. I criteri di valutazione fondamentali sono revisione: N/D; Consiglio di Amministrazione: N/D; diritti degli azionisti: N/D; retribuzione: N/D.